Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT03141684
- Locations
- 🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 162
- Registration Number
- NCT03138889
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇩🇪Lungenklinik Hemer, Hemer, Germany
🇺🇸Highlands Oncology Group, PA - North Hills, Fayetteville, Arkansas, United States
Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Grand Hôpital de Charleroi
- Target Recruit Count
- 54
- Registration Number
- NCT03127007
- Locations
- 🇧🇪
GHdC, Charleroi, Hainaut, Belgium
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇧🇪Hôpital Erasme, Brussels, Belgium
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT03125928
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT03120676
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT03115801
- Locations
- 🇺🇸
Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York, United States
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
- Conditions
- Appendix AdenocarcinomaRare LesionSkin Squamous Cell CarcinomaMetastatic Malignant NeoplasmRare Neoplastic SyndromeLocally Advanced Skin Squamous Cell CarcinomaMetastatic Skin Squamous Cell CarcinomaMetastatic Small Intestinal AdenocarcinomaRefractory Malignant NeoplasmStage IV Small Intestinal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT03108131
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Atezolizumab Immunotherapy in Patients With Advanced NSCLC
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 64
- Registration Number
- NCT03102242
- Locations
- 🇺🇸
EMMC Cancer Care, Brewer, Maine, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT03101280
- Locations
- 🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸La Paz University Hospital, Madrid, Spain
🇫🇷Centre Hospitalier Lyon Sud; Service d'Oncologie Médicale, Pierre Benite, France
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03093922
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.